The US Food and Drug Administration (FDA) has granted clearance for medical device firm Valorem Surgical’s MaxiMIS Spinal Fixation System.

The company, which has a viable portfolio of minimally invasive (MIS) spine solutions pending FDA clearance, announced the first case using its MaxiMIS Spinal Fixation System was performed by neurosurgeon, Dr Jae Lim in Reston, US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The system was developed for posterior pedicle screw fixation of the non-cervical posterior spine in skeletally mature patients.

Valorem Surgical president Joseph Jin said: "The MaxiMIS launch, coupled with our commitment to cost containment directives, comes at an opportune time to meet demand in the healthcare and orthopaedic device industry.

"The system was developed for posterior pedicle screw fixation of the non-cervical posterior spine in skeletally mature patients."

"We have addressed and improved upon the clinical shortages of existing systems, and remain focused on our goal of developing advanced, minimally invasive technology that enables surgeons to improve patient outcomes and reduce the associated costs of care."

See Also:

It is claimed the system will offer stabilisation and immobilisation of spinal segments as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company said the system was designed for a minimally invasive approach for less tissue disruption, blood loss and trauma.

It is currently available as a minimally invasive or open screw system in sizes from 4mmx25mm to 10mmx100mm, in monoaxial, polyaxial and cannulated variations.

The company plans a limited market release of the system at the end of the first quarter of 2015. A complete launch is scheduled for the second quarter of 2015.